title: Anhedonia and social adaptation predict substance abuse evolution in dual diagnosis schizophrenia.
abstract: The current study sought to identify the variables, derived from the self-medication hypothesis, which predicted substance abuse evolution during a homogeneous 3-month antipsychotic treatment. Twenty-four patients were diagnosed with schizophrenia and substance abuse (mainly cannabis and alcohol). Substance abuse, psychiatric symptoms, anhedonia, and social adjustment were assessed at baseline and study endpoint. Linear regression analyses were performed. Better social adaptation and worse anhedonia predicted substance abuse improvements. Conversely, greater psychoactive substance (PAS) use predicted endpoint positive and depressive symptoms. These results suggest that: (i) substance abuse interferes with psychiatric prognosis in schizophrenia; and (ii) dual diagnosis treatments leading patients to engage in alternative social activities may render substance abuse less appealing. Further studies are warranted to dissociate the causes and consequences of substance abuse in schizophrenia.
authors.affiliation: Fernand-Seguin Research Center, Louis-H. Lafontaine Hospital, Montreal, Canada.
authors.forename: Stéphane
authors.initials: S
authors.lastname: Potvin
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Stip
authors.forename: Olivier
authors.initials: O
authors.lastname: Lipp
authors.forename: Marc-André
authors.initials: MA
authors.lastname: Roy
authors.forename: Marie-France
authors.initials: MF
authors.lastname: Demers
authors.forename: Roch-Hugo
authors.initials: RH
authors.lastname: Bouchard
authors.forename: Alain
authors.initials: A
authors.lastname: Gendron
mesh_terms: D000328:Adult; D000342:Affective Symptoms / Q000175:diagnosis* / Q000453:epidemiology / Q000523:psychology*; D019973:Alcohol-Related Disorders / Q000175:diagnosis / Q000453:epidemiology / Q000523:psychology; D014150:Antipsychotic Agents / Q000627:therapeutic use; D001290:Attitude; D016739:Behavior, Addictive / Q000523:psychology; D015897:Comorbidity; D017831:Diagnosis, Dual (Psychiatry); D005260:Female; D006801:Humans; D008297:Male; D002189:Marijuana Abuse / Q000175:diagnosis / Q000453:epidemiology / Q000523:psychology; D008960:Models, Psychological; D009042:Motivation; D011379:Prognosis; D011619:Psychotropic Drugs / Q000009:adverse effects; D012044:Regression Analysis; D012559:Schizophrenia / Q000175:diagnosis* / Q000188:drug therapy / Q000453:epidemiology; D012565:Schizophrenic Psychology; D012651:Self Medication / Q000523:psychology; D012917:Social Adjustment; D019966:Substance-Related Disorders / Q000175:diagnosis* / Q000188:drug therapy / Q000453:epidemiology
chemical_list: D014150:Antipsychotic Agents; D011619:Psychotropic Drugs